Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2016-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.leukres.2016.09.019PMID 27710869
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

  2015cited by this paper
• The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

  2015cited by this paper
• Dasatinib promotes Th1-type responses in granzyme B expressing T-cells

  2014cited by this paper
• Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)

  2014cited by this paper
• The use of multiplex platforms for absolute and relative protein quantification of clinical material

  2014cited by this paper
• Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche.

  2014cited by this paper
• Immunology and Immunotherapy of Chronic Myeloid Leukemia

  2014cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

  2013cited by this paper
• Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

  2013cited by this paper
• Deciphering and reversing tumor immune suppression.

  2013cited by this paper
• Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

  2013cited by this paper
• Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib

  2012cited by this paper
• Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.

  2012cited by this paper
• Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

  2012cited by this paper
• Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

  2012cited by this paper
• Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

  2011cited by this paper
• Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.

  2011cited by this paper
• Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.

  2011cited by this paper
• Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

  2010cited by this paper
• TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010cited by this paper
• Does Imatinib Mesylate Therapy Cause Growth Hormone Deficiency?

  2009cited by this paper
• Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia

  2008cited by this paper
• Regulation of Hematopoietic Stem Cells by the Steel Factor/KIT Signaling Pathway

  2008cited by this paper
• Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

  2008cited by this paper
• FLT3, CD32, PU.1, ERG, uPAR, and TAP2 Are Strongly Associated with the Progression of Chronic Myeloid Leukemia and Combination of Small Interference RNA of FLT3 and STI571 Synergistically Induced Apoptosis of K562 Cells

  2008cited by this paper
• VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues

  2007cited by this paper
• Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

  2007cited by this paper
• Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

  2007cited by this paper
• Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Multiplexed protein measurement: technologies and applications of protein and antibody arrays

  2006cited by this paper
• The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.

  2005cited by this paper
• Allogeneic Myelo-Ablative Stem Cell Transplant (SCT) as Salvage Therapy of Reduced-Intensity Conditioned (RIC) SCT: Toxicity and Outcome.

  2005cited by this paper
• Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

  2004cited by this paper
• CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review

  2004cited by this paper
• Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow.

  2003cited by this paper
• bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use

  2001cited by this paper
• Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.

  2000cited by this paper
• Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.

  2000cited by this paper
• Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

  2000cited by this paper
• Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.

  2000cited by this paper
• The biology of chronic myeloid leukemia.

  1999cited by this paper
• Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee.

  1998cited by this paper
• Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review

  1998cited by this paper
• Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro

  1996cited by this paper
• The CD40 antigen and its ligand.

  1994cited by this paper
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia

  1984cited by this paper
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

  1984cited by this paper

• Olink Proteomics in Heart Failure: A Comprehensive Review of Applications From Biomarker Discovery to Pathophysiological Insights and Clinical Implementation

  2026influential citation
• The Depth of the Molecular Response in Patients with Chronic Myeloid Leukemia Correlates with Changes in Humoral Immunity

  2024cites this paper
• Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects

  2023cites this paper
• Staphylococcus Aureus and Streptococcus Pyogenes Induce Psoriasis-Related Transcriptomes Augmented by IL-17A and TNF-α.

  2023cites this paper
• IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors

  2022cites this paper
• Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay

  2021cites this paper
• Spontaneously Resolved Atopic Dermatitis Shows Melanocyte and Immune Cell Activation Distinct From Healthy Control Skin

  2021cites this paper
• Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID‐19 patients

  2021cites this paper
• Th2/Th1 Cytokine Imbalance Is Associated With Higher COVID-19 Risk Mortality

  2021cites this paper
• An Exploratory Analysis of Changes in Circulating Plasma Protein Profiles Following Image-Guided Ablation of Renal Tumours Provides Evidence for Effects on Multiple Biological Processes

  2021cites this paper
• Expression Dynamics Of The Immune Mediators ARG1, TBET, CIITA, IL10 AND TGFB1 IN Chronic Myeloid Leukaemia Patients During The First Year Of Imatinib Therapy.

  2021cites this paper
• Targeting Tumor-Induced Immunosuppression Using Conventional Cancer Therapeutics

  2021cites this paper
• Cross-sectional study of blood biomarkers of patients with moderate-to-severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation.

  2020cites this paper
• The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature.

  2020cites this paper
• Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.

  2020cites this paper
• Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib

  2020cites this paper
• Single-cell transcriptomics combined with interstitial fluid proteomics defines cell-type-specific immune regulation in atopic dermatitis.

  2020cites this paper
• Increased cardiovascular and atherosclerosis markers in blood of older atopic dermatitis patients.

  2019cites this paper
• Effect of food intake on 92 oncological biomarkers by the Proseek Oncology II panel

  2019cites this paper
• The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib.

  2019cites this paper
• The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease.

  2019cites this paper
• The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study†

  2019cites this paper
• Clinical and Immunological Studies in Chronic Myeloid Leukaemia

  2017cites this paper
• The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins

  2017cites this paper